We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

TATAA Biocenter Expands its Digital PCR Offerings

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

TATAA Biocenter is expanding its digital PCR offerings with Bio-Rad’s high-throughput QX200™ Droplet Digital™ PCR system (ddPCR™).

In 2007 TATAA Biocenter became the first company in Europe to provide digital PCR services to researchers and published one of the first papers that featured an application of digital PCR on a high throughput platform (Nucleic Acids Research 36: 387, 2008).

The paper discussed using digital PCR to measure intracellular mRNA gradients. TATAA also co-authored the Guidelines for Minimum Information for Publication of Quantitative Digital PCR Experiments (Clinical Chemistry 59:6, 2013). (publication names should be in italics).

“Digital PCR is most important complement to qPCR and can be used for standardization, copy number variation, and rare mutation analysis,” said Dr. Mikael Kubista, founder and CEO of TATAA Biocenter.

Dr. Kubista continued, “We have previously adopted the OpenArray and BioMark digital PCR platforms from Life Technologies and Fluidigm, which offer simultaneous measurements of qPCR and highly specific and sensitive dPCR analysis; however, with Bio-Rad’s QX200 system we can now offer dPCR in high throughput, using a much larger number of partitions. This is major strengthening of our service and training offerings.”